REGN Quote, Financials, Valuation and Earnings

Amgen has a net margin of 36.03% compared to Regeneron Pharmaceuticals's net margin of 33.28%. Regeneron Pharmaceuticals's return on equity of 17.19% beat Amgen's return on equity of 65.35%.

Regeneron Pharmaceuticals has a consensus price target of $1,053.08, signalling upside risk potential of 50.04%. On the other hand Amgen has an analysts' consensus of $322.43 which suggests that it could grow by 22.42%. Given that Regeneron Pharmaceuticals has higher upside potential than Amgen, analysts believe Regeneron Pharmaceuticals is more attractive than Amgen.

Regeneron Pharmaceuticals has a beta of 0.084, which suggesting that the stock is 91.622% less volatile than S&P 500. In comparison Amgen has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.307%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.42% to investors and pays a quarterly dividend of $2.25 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Amgen pays out 67.83% of its earnings as a dividend. Amgen's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regeneron Pharmaceuticals quarterly revenues are $3.7B, which are smaller than Amgen quarterly revenues of $8.5B. Regeneron Pharmaceuticals's net income of $1.3B is lower than Amgen's net income of $2.8B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 17.37x while Amgen's PE ratio is 33.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.83x versus 4.37x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

Biogen has a net margin of 36.03% compared to Regeneron Pharmaceuticals's net margin of 15.76%. Regeneron Pharmaceuticals's return on equity of 17.19% beat Biogen's return on equity of 10.52%.

Regeneron Pharmaceuticals has a consensus price target of $1,053.08, signalling upside risk potential of 50.04%. On the other hand Biogen has an analysts' consensus of $242.83 which suggests that it could grow by 65.79%. Given that Biogen has higher upside potential than Regeneron Pharmaceuticals, analysts believe Biogen is more attractive than Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals has a beta of 0.084, which suggesting that the stock is 91.622% less volatile than S&P 500. In comparison Biogen has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.074%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Regeneron Pharmaceuticals quarterly revenues are $3.7B, which are larger than Biogen quarterly revenues of $2.5B. Regeneron Pharmaceuticals's net income of $1.3B is higher than Biogen's net income of $388.5M. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 17.37x while Biogen's PE ratio is 13.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.83x versus 2.23x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 36.03% compared to Regeneron Pharmaceuticals's net margin of 8.48%. Regeneron Pharmaceuticals's return on equity of 17.19% beat Eli Lilly and's return on equity of 66.4%.

Regeneron Pharmaceuticals has a consensus price target of $1,053.08, signalling upside risk potential of 50.04%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 28.17%. Given that Regeneron Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Regeneron Pharmaceuticals is more attractive than Eli Lilly and.

Regeneron Pharmaceuticals has a beta of 0.084, which suggesting that the stock is 91.622% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.30 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regeneron Pharmaceuticals quarterly revenues are $3.7B, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Regeneron Pharmaceuticals's net income of $1.3B is higher than Eli Lilly and's net income of $970.3M. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 17.37x while Eli Lilly and's PE ratio is 83.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.83x versus 16.99x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 36.03% compared to Regeneron Pharmaceuticals's net margin of 25.23%. Regeneron Pharmaceuticals's return on equity of 17.19% beat Pfizer's return on equity of 4.63%.

Regeneron Pharmaceuticals has a consensus price target of $1,053.08, signalling upside risk potential of 50.04%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.88%. Given that Regeneron Pharmaceuticals has higher upside potential than Pfizer, analysts believe Regeneron Pharmaceuticals is more attractive than Pfizer.

Regeneron Pharmaceuticals has a beta of 0.084, which suggesting that the stock is 91.622% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.37% to investors and pays a quarterly dividend of $0.42 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Regeneron Pharmaceuticals quarterly revenues are $3.7B, which are smaller than Pfizer quarterly revenues of $17.7B. Regeneron Pharmaceuticals's net income of $1.3B is lower than Pfizer's net income of $4.5B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 17.37x while Pfizer's PE ratio is 35.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.83x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.